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Abstract
Lassa fever (LF) and Ebola Hemorrhagic Fever (EHF) are viral diseases endemic to West
Africa.The etiological agent of Lassa fever is an enveloped virus from the Arenaviridae family
and was first discovered in 1969 when two missionary nurses died of a mysterious illness in the
town of Lassa in Borno state, Nigeria.1 This virus is animal-borne (zoonotic) and is carried by
the animal vector Mastomys natalensis (multimammate rat). The Ebola virus is also zoonotic
originating from fruit bats belonging to the Pteropodidae family.2 The first reported case of
Ebola Virus Disease (EVD) was a principal who was believed to have visited the Ebola river on
his journey through the Democratic Republic of Congo.
Annually, there are about 100,000 to 300,000 reported cases of Lassa fever, with about
5,000 deaths.1 Concurrently, the Ebola virus has raked in 11,310 reported deaths from about
28,616 suspected cases, 10% of which were health professionals.3 It is noteworthy, however, that
the death toll associated with EVD is more sporadic and widespread than that of LF. Most
infections can be attributed to person-person transmission in which healthy individuals get
infected by coming in contact with the body fluids (urine, saliva, and semen) of the sick.1
Both the Lassa and Ebola viruses are pertinent in current public health discussions
especially for their potential as bioweapons.1,2 Consequently, this paper seeks to discuss the
structure and pathogenic mechanisms of both viruses, address current treatments and
complications, and propose areas for further research and preventive measures.

Keywords:Lassa virus (LASV), Ebola Virus (EBOV), Lassa Fever (LF), Ebola Virus Disease
(EVD), Ebola Hemorrhagic Fever (EHF), Sensorineural Hearing Loss (SNHL), Ribavirin
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CHAPTER ONE:INTRODUCTION
Part I: The Lassa Virus
The Lassa virus
(LASV)

is

enveloped

an
virus

belonging to the
genus Arenavirus
and

the

family

Arenaviridae.5,6

Like other viruses,
the LASV infects a host organism
(typically humans) and hijacks cell
machinery thereby causing the cells to create more viruses that go on to infect other cells.6
The genome of LASV consists of two single-stranded RNA species designated small (S)
and large (L) which is characteristic of all arenaviruses
(see Figure 1).7,8,9 Arenaviruses are divided into two
groups based on their rodent hosts: the New World
arenaviruses and the Old World arenaviruses.9,10 The
Mastomys

natalensis

(commonly

called

the

multimammate rat) is the primary host of
the LASV (see Figure 2).11 Its habitats
range from savannas and forests to farm lands and urban areas.11 Consequently, Lassa fever
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(LF), which is a hemorrhagic fever caused by LASV is endemic in West African countries like
Nigeria, Sierra Leone, Liberia, and Guinea where these rats and their habitats are prevalent (see
Figure 3).12 It was first discovered in 1969 when two missionary nurses died in Nigeria and
received its name from the
town

called

Lassa

in

Northern Nigeria where these
first

cases

occurred.13

Humans presumably become
infected through contact with
infected

rodent

excreta,

tissues,

or

blood.8

Person-to-person
transmission of Lassa fever
can also occur.9 Additionally,
pregnant

women

in

the

third-trimester are most susceptible to contracting the virus. Between January 1996 and March
1997, over 1,000 cases of Lassa fever with 148 deaths were reported from eastern Sierra
Leone.14,15
Additionally, many of the countries affected by this disease are also endemic regions for malaria
epidemics.16,17 Unfortunately, malaria presents with similar symptoms as Lassa fever does.17
Some of the symptoms include fatigue, general weakness, fever, headache, and a sore throat
which can also be referred to as general malaise.18, 10 Some of the other symptoms associated
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with LF like vomiting, diarrhea, face swelling, low blood pressure, and nose bleeding can also be
misdiagnosed as Dengue or Yellow Fever.19 Thus, the only sure-fire diagnostic method is by
using enzyme-linked immunosorbent serologic assays (ELISA), which detect IgM and IgG
antibodies as well as the Lassa antigen.5 It was discovered that these antigens have minute
variations depending on the origins of the viral isolates.20 Using genomic sequencing they were
able to categorize these strains into three groups, namely the prototype LP strain from
northeastern Nigeria,11 the GA 391 strain from central Nigeria,12 and the Josiah strain from Sierra
Leone.10 The LP strain is also called the native LASV strain because it is predominantly found in
the town of Lassa, Borno State where the virus was first discovered.20
Regardless of the viral strain, however, there is currently only one way to treat a LASV
infection.18 The disease has no cure or vaccine, but experimentation continues to be done on
monkeys like Cynomolgus macaques because their response to the virus has been most similar to
humans. Researchers have avoided mice models because they are too close to the host species
Mastomys natalensis and thus do not
have an immunogenic response to the
virus.15


Additionally, Ribavirin which
was initially approved as a treatment
for severe respiratory syncytial virus
(RSV) in children has been found to
alleviate the symptoms of LF.20 This
drug is an analogue to guanosine (a purine nucleoside comprised of guanine attached to a ribose
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sugar which is involved in a variety of cellular function including the synthesis of nucleic acids
and proteins, as an ATP substitute, and in intracellular signal transduction).20 Twenty years after
its initial discovery, in the early 1990s, Ribavirin began to be used as a monotherapy treatment
for Hepatitis C Virus (HCV).20

At least half of the patients treated with Ribavirin had

improvements in their serum aminotransferase levels, but the viral levels of HCV in these
patients did not relent even after prolonged treatment.21
Apart from direct antiviral effects Ribavirin has been found to have immunomodulatory
ones as well. In patients, Ribavirin induced a switch in T-helper (TH) cells from TH2 to TH1 (see
Figure 5 mechanism a).22 Helper T cells are important players in the adaptive immune system.
TH1

cells

specifically

are

pro-inflammatory
which means they
secrete
that

cytokines

increase

the

inflammatory
response.22

These

cytokines,
interferon-γ (IFN-γ)
and tumor necrosis
factor-α

(TNF-α),

activate macrophages to kill microbes and cytotoxic T lymphocytes (CTLs) to kill infected cells.

Amali-Adekwu 8

Once inside the cell, Ribavirin is phosphorylated to its GMP, GDP, and GTP analogues which
are RMP, RDP, and RTP respectively.22,23 Research by Maag et al. showed that a
misincorporation of RTP by RNA polymerase in place of GTP can block RNA elongation and
lead to premature termination which would inhibit viral spread (see Figure 5 mechanism c.).22
This only occurs at high concentrations of the drug, however, so it was assumed that this was not
the main mechanism of action in HCV infections.22 Another possible candidate for the Ribavirin
mechanism is its action as a competitive inhibitor of inosine monophosphate dehydrogenase
(IMPDH) (Figure 5 mechanism b).22 IMPDH is an enzyme that catalyzes the rate-limiting step of
GTP and ATP synthesis:inosine-5-phosphate (IMP) to xanthosine monophosphate (XMP) which
is subsequently converted to GMP/AMP by GMP/AMP synthetase.22 Consequently, Ribavirin
leads to the depletion of GTP which is necessary for viral RNA synthesis.23
Unlike human polymerases that check and recheck RNA/DNA to ensure the fidelity of
the transcripts, HCV RNA polymerase is less concerned about mutations because they are
usually beneficial to the virus.23 Crotty et al. proposed that ribavirin might act as a viral mutagen
and increase the frequency of mutations in the virus (Figure 5 mechanism d).24 At some point,
these mutations become detrimental to the virus and lead to “error catastrophe”.24,25
Unfortunately, studies have shown that these mechanisms are not effective enough to completely
stem a viral load.23,24 Thus current treatments with Ribavirin are supplemented with interferon
alpha (IFN- ).26 IFN-

induces IFN-stimulating genes which establish a non-virus-specific

antiviral state with the infected cell which eventually lead to protein degradation, inflammatory
cell responses and apoptosis.26 When administered together, Ribavirin seems to amplify or
stabilize the activity of IFN- .26
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All things considered, scientists are still unsure how the drug works on the LASV, but it
is suspected that the drug might be acting on the viral RNA and blocking its translation to
proteins in the host cells either by mechanisms b or c pictured in Figure 5.27 Additionally, the
drug only seems to have this effect if administered early in the infection which could be due to
the fact that the virus has not had much time to replicate or spread systemically allowing
Ribavirin to effectively depress viral
activity. 27

Part II: Ebola Virus
Ebola, also known as the Ebola
Virus

Disease

(EVD)

or

Ebola

Hemorrhagic Fever (EHF) is a severe and
often fatal disease in humans.28 The
Ebola virus (EBOV) was first discovered
in

1976

when

there

were

two

simultaneous outbreaks in the towns of Nzara, South Sudan and Yambuku, Democratic Republic
of Congo as shown in Figure 6.28 The disease actually got its name from the Ebola river in
Congo.28 The Ebola virus belongs to the Filoviridae family in which there are five different
variants or species: Zaire (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Reston (RESTV), and
Tai Forest (TAFV).28 The first three have been associated with large outbreaks in Africa, the
most recent of which being the Zaire outbreak in West Africa in 2014.28
EBOV is a filamentous virion containing linear negative-stranded RNA.29 The virus
encodes for seven proteins which direct the synthesis of eight proteins.29 GP proteins on the
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surface of the virus mediate the attachment of the virus to host cells and the subsequent fusion of
the viral and host membranes.29 EBOV is
believed

to

enter

the

cell

via

receptor-mediated endocytosis. Previously,
it was believed that the VP24 and matrix
VP40 proteins on the virus were minor
structural components solely involved in
viral nucleocapsid formation, viral budding
or assembly, and host range determination.28
Current research, however, suggests that VP24 might be involved in blocking interferon
signaling. Interferons are signaling proteins released by infected host cells in response to the
presence of viruses, bacteria, parasites, or tumor cells.29 These interferons act as warning signals
to neighbouring cells alerting them of a potential infection.30 It is assumed that the other
components of the virion structure including its nucleoprotein(N), VP35,VP30, and L proteins
are involved in stabilizing the RNA in its helical conformation.28
Much like the Lassa virus, the Ebola virus is transmitted from animals to humans and
through the human population by contact with contaminated surfaces or materials like bedding or
clothing that have been exposed to body fluids of infected individuals.11,28 All strains of the virus
except for RESTV are pathogenic to humans.31 It is believed that the original (natural) hosts of
the virus were fruit bats of the Pteropodidae family (Figure 8). It was introduced into the human
population by contact with the blood, organs, and other body fluids of infected chimps, gorillas,
monkeys, antelopes, and porcupines.31
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The incubation period for the virus is between 2 and 21 days and humans are not
infectious until they present symptoms.31 The
first symptoms of an infection are very similar
to those of Lassa fever, malaria, and other
endemic illnesses and can only be effectively
diagnosed using an ELISA; however, a major
difference is the fact that the major complication
of Ebola impair kidney and liver functions.32 On
average the fatality rate for an EVD infection is
about 78% and the virus can survive in semen
for between 3 and 12 months even after recovery. There is currently no cure or proven treatment
for EVD, but supportive care including rehydration with oral or intravenous fluids has been the
most common way of maintaining patients.32,33
After the most recent outbreak of EVD in August 2014, research began on the
recombinant vesicular stomatitis virus (rVSV). Vesicular stomatitis is a viral disease that
primarily affects horses and cattle, but can also be harmful to swine, sheep, goats, and llamas.34
Humans are rarely affected by this disease even when they come into contact with infected
animals, however, the recombinant form of VSV has been mutated to express the filovirus
glycoprotein (GP): rVSV-ZEBOV. Upon administration to monkeys it was found that it
protected them from Ebola and Marburg virus infections both as a prophylactic and
postexposure.35 As of April 2016, phase trials for the rVSV-ZEBOV vaccine had begun in
Gabon, Kenya, Germany, and Switzerland.36 The vaccine was given intramuscularly into the
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deltoid at different concentrations and it was noted that 11 of the 51 participants in Geneva
complained of arthralgia and developed skin lesions.36 Nonetheless, they discovered high levels
of neutralizing antibodies in the blood plasma which lasted in the blood for about 180 days.36
This research holds promise because it suggests that the recombinant virus is immunogenic in
humans and the next step would be to test how effectively these antibodies bind to and neutralize
the EBOV virus both in vitro and in vivo.36


\
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CHAPTER TWO: LITERATURE REVIEW
Part I: What Do We Know?
Viral Mechanisms and Pathogenesis
While the Lassa and Ebola viruses belong to different virus families they share
similarities in their mechanisms of pathogenesis.37 In vitro experiments suggest that both viruses
infect macrophages and endothelial cells at the onset of the infection.37 Macrophages and
endothelial cells play an important role in the innate immune system. The innate immune system
is the body’s general response to a pathogen.38 It is considered the next line of defense after a
pathogen or foreign substance has
already passed through the skin or the
mucosa

lining

the body’s

orifices.38 The innate response
is nonspecific and involves a
variety of proteins (interferons,
antimicrobial

proteins,

and

complement) and phagocytic
cells

(like neutrophils and

macrophages) which recognize
foreign antigens and quickly
activate

the

inflammatory

response (Figure 9). The inflammatory response is activated when these phagocytic cells as well
as other cells involved in the nonspecific innate response begin to secrete cytokines/chemokines
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that attract other important immune cells (like B and T Lymphocytes) to the infected area (Figure
9).39 It is believed that both the Lassa and Ebola viruses activate similar innate response
pathways and trigger the rapid and uncontrolled release of cytokines, or inflammatory
mediators.40 Dendritic cells (DCs) are also key players of the innate immune system because they
act as antigen presenting cells to B and T lymphocytes.40 Current research show that both viruses
have contradicting effects on these different cell populations ie. they activate macrophages and
endothelial cells to release cytokines and activate an immune response, while they use DCs to
replicate and inhibit them from releasing cytokines or synthesizing the costimulatory proteins
necessary for antigen presentation.40 This also serves to slow down or possibly inhibit the
adaptive immune response to the infection.
The mechanism for the Lassa Virus is the least understood of the two, however more
recent research showed that T-cells play a dual role of not only protecting the infected organism
from LASV, but also in enhancing LF pathogenesis.35 In this experiment the scientists used
genetically engineered (HHD) mice which were susceptible to LF because they had human T
cells.41 This theory is supported by the fact that macrophages also act as antigen presenting cells
and the costimulatory effects of the T cells they bind to can further activate them to secrete
inflammatory mediators, thereby increasing the immune response.41 In the case of Lassa fever, it
seems that it is postulated that with increasing viremia, T cells continue to encounter LASV
epitopes on the macrophages and thus continue to stimulate them as well.41 This overstimulation
of the macrophages leads to severe hepatic and pulmonary damage, in addition to the shock
syndrome associated with Lassa Fever. Mammalian studies have further supported this theory by
showing the seemingly paradoxical observation that high doses of LASV tend to be less lethal
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than low ones.42 This might seem to contradict the previous experiment, but in reality it follows
the kinetic model of proteins.42 In the sense that there is a concentration at which the virus
reaches its maximum virility. At that point all the T cells are “exhausted” and are no longer
available to overstimulate the macrophages.42 This attenuates the disease making it less fatal.
Thus, on the one hand it seems that the adaptive immune system is a necessary part of the battle
against the virus and on the other it might increase its adverse effects.42
Similar to the LASV, the Ebola Virus initially infects macrophages and dendritic cells.43
One characteristic difference between the two, however, is the fact that Ebola presents with a
cytokine storm, which is typical of many hemorrhagic diseases.43 A cytokine storm is a secretion
of

numerous

pro-inflammatory

cytokines and induces contradictory
signals that adversely affect immune
cells and other tissues of the body.43
The Ebola virus seems to primarily
affect the spleen and kidneys in
addition to the immune system. This
is important to note because these two organs are involved in maintaining the body’s fluid and
chemical balance as well as the blood supply of coagulation factors.44 Additionally, the EBOV is
able to invade almost all human cells by using attachment mechanisms like receptor-mediated
endocytosis and macropinocytosis (Figure 10). Viral activation leads to a steady increase in the
production of proinflammatory cytokines and chemokines including IL-1β, IL-1RA, IL-6, IL-8,
IL-15, IL-16, MIP-1α, MIP-1β, MCP-1, MIF, IP-10 GRO-α and eotaxin (Figure 11).45 Disease
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progression also leads to the nitric oxide production which dilates and increases the permeability
of blood vessels.45 These changes trigger the coagulation cascade which leads to widespread
elevated thrombomodulin and
ferritin levels. Thrombomodulin
is a protein cofactor expressed
on endothelial cell surfaces.46 Its
function is to modify thrombin
which is an essential component
of the coagulation pathway.
Thrombin is the enzyme that
converts fibrinogen to fibrin which
eventually forms the fibrous mesh
associated with a clot.46 Ferritin is an intracellular protein that stores iron.46 Excess amounts of
these proteins play a role in the formation of blood clots (Disseminated Intravascular
Coagulation; DIC) that could possibly inhibit the flow of blood to vital organs like the liver,
brain, or kidneys which could lead to the tissue damage associated with EVD.46
Given the fact that the Ebola virus is on average more lethal than the Lassa virus, the
major complication associated with this disease is sepsis.31 Sepsis can be defined as the systemic
inflammatory response to an infection.31 It can cause a variety of responses from shock, and
multiple organ failure to death.31 EBOV activates classical sepsis in which pattern recognition
receptors like toll-like receptors (TLRs) or nucleotide-binding oligomerization domain
(NOD)-like receptors initiate systemic inflammation.31 At the same time, the can lead to
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immunosuppression which would make the body more susceptible to infection by other
microorganisms.31
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Part II: Where Can We Go?
Future Studies and Research Proposal
Of the two viruses Ebola has received the most recognition with global research efforts
focusing on vaccines and treatment regimes for a virus that could potentially be a pandemic
someday. The Lassa virus which is more prevalent in third world countries does not receive the
same amount of interest either due to lack of funding from the failing health sectors of West
Africa, or a general disinterest in something that is not as “imminently” threatening as Boko
Haram terrorist, famine, malaria, or drought. For this reason, it is important that West Africa
begins a conversation on the subject of Lassa fever and how to eradicate it from the society.
One of the biggest complications of Lassa fever is hearing loss. Statistics show that of the
people infected with the LASV, 25% will develop hearing loss.10 Unlike the other
symptoms/complications of the disease like hypovolemic shock or hemmoraghing which can be
accounted for by the viral mechanism of action in vivo, no one really understands what happens
in the progression of the disease to cause hearing loss.10
Virus-associated hearing loss is not a new concept in virology. Many viruses including
the West Nile Virus, the mumps virus, the Varicella Zoster virus, and the measles virus have all
been found to cause some degree of sensorineural hearing loss in infected patients.47-50 In these
cases, the hearing loss is as a result of an acute infection and occurs as soon as the subjects are
exposed to the virus.50 Additionally, the patient spontaneously recovered his or her ability to hear
once the infection has passed. Some LASV associated hearing loss has been reported to behave
in this manner as a result of an acute infection, but sometimes patients have been found to
develop hearing loss during the convalescence phase of their illness as well. Researchers believe
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that this could be a result of an autoimmune response resulting from the virus activating immune
cells in the infected patients.51 In these cases, even though the viral titer was low, the activated
immune cells were primed and ready to attack the ear leading to sensorineural hearing loss.51
The dynamics of the immune system and the role it plays in the propagation of the
disease has been identified as a potential factor in the occurrence of the most common
complication of LF: Sensorineural Hearing Loss (SNHL). Hearing, or auditory perception, is the
ability to perceive sound by detecting vibrations in the surrounding air.50 The pinna directs sound
waves through the external auditory canal to the tympanic membrane all of which are part of the
outer ear (see Figure 13).50 At the tympanic membrane sound vibrations are transmitted to the
ossicles of the middle ear which amplify the sound before it gets to the cochlea.50-51 Hair cells in
the cochlea (the inner ear) are involved in transducing that sound wave into electrical impulses
that can be transmitted through the
vestibulocochlear nerve to the temporal
lobe of the brain where it is
perceived as sound.52
Sound waves can be
classified
frequencies

based

on

their

and intensities.52

The frequency of a sound is
measured in hertz (Hz) and
dictates its pitch. The range for
typical human hearing is 20-20000Hz, with conversation frequencies in the 300-3000 Hz range,
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clapping between 2,200 and 2,800Hz, and the sound from crickets within the 4000-5000 Hz
range.53 The intensity of a sound is measured in decibels (dB) and it dictates how loud a sound is.
A whisper is about 15dB, a normal conversation about 60 dB, and a car horn is typically
110dB.53
Sometimes things can go wrong with the hearing process and hearing loss occurs. There
are three types of hearing loss namely conductive, sensorineural, and mixed.50 Conductive
hearing loss affects the outer and middle ear and is characterized by foreign bodies or
malformations that impede the sound waves from arriving at their destination.52 Sensorineural
hearing loss (SNHL), on the other hand, affects the inner ear and is also known as nerve-related
hearing loss. This type of hearing loss is usually caused by excessive exposure to loud noises,
head trauma, viruses or diseases. SNHL also tends to be irreversible.53,54 Finally, mixed hearing
loss is a combination of both conductive and sensorineural hearing loss. Hearing loss can be
measured as either an absolute inability to hear a certain sound frequency or as a degree of loss
that affects only sounds of certain intensities/loudness.
Due to the fact that hearing loss is the most common and least understood complication
of this disease and the goal of this proposal is to identify the presence or lack thereof of a
correlative relationship between certain viral strains and the incidence of hearing loss.8
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Specific Aims
1. T
 o determine what strains of the Lassa virus cause sensorineural hearing loss (SNHL) in
Cynomolgus macaques with functional and depressed immune systems.
Hypothesis: The combination of a heightened immune system and the most native strain of the
Lassa virus (the NP strain) would increase the likelihood of hearing loss in the subjects.
2. T
 o test the effects of Ribavirin treatment on hearing loss in the affected group from the first
specific aim.
Hypothesis: Ribavirin will have little to no effect on hearing loss unless administered early.
Research Design and Methods
The subject model for this experiment is the Cynomolgus macaque. Cynomolgus
macaques are a species of monkeys that have previously been used in studies with LASV
because they have been found to respond to the virus with symptoms similar to humans.15
Researchers have avoided mice models because they are too close to the host species Mastomys
natalensis and thus do not have an immunogenic response to the virus.15
I. The first specific aim is to determine what strains of the Lassa virus cause
sensorineural hearing loss (SNHL) in Cynomolgus macaques with functional and
depressed immune systems.
A. The subject group would be 16 Cynomolgus macaques
B. These macaques would all be initially exposed to the Brain Auditory Evoked Response
(BAER) test in which they would have nodes put in their ears and a sound would be
released at a certain frequency (see Figure 14). The movement of the sound wave would
be tracked to the brain with peaks being identified at the auditory nerve, pons, and
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midbrain. Once it is ensured that the subjects have functional hearing, they would be split
into two groups with 8 macaques
in each.
C. One group of macaques would be
given pure drinking water, while
the other group will be given
nicotine-spiked drinking water for
a period of 2 weeks. Prior studies
have shown that nicotine depresses
the immune system, thus these macaques
would constitute the immunosuppressed
(IS) subject group with the other macaques being the immunocompetent (IC) group.
D. The next step would be to divide the subjects once again into four groups: control, LP
strain, GA391 strain, and the Josiah strain groups. The groups receiving the viral strains
would be given 1 mL injections intravenously (see Figure 15).
E. Subjects would be allowed to run
the course of the illness for about 3
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weeks, and the hearing test would be performed weekly to determine if there is any
hearing loss.
Expected Results:According to research conducted by Okokhere12, the majority of the
documented hearing loss cases occurred in northeastern Nigeria. This area is where the NP or
native strain of the LASV is prevalent. Thus, I would expect that the macaques exposed to this
strain would be most likely to develop hearing loss. Additionally, based on previous research
which suggest that the immune system might play a role in the incidence of hearing loss.18 I
would expect that the immunocompetent (IC)+NP strain would be even more likely to have
hearing loss, or a greater degree of hearing loss than the immunosuppressed (IS)+NP strain. The
presence of hearing loss would be identified by a BAER test similar to the right side result in
Figure 14 in which many or all the previously seen peaks have tapered out.
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II. The second specific aim is to test the effects of Ribavirin treatment on hearing loss in
the affected group from the Specific Aim I.
A. In this experiment, the subject group would be 16 macaques exposed to the same
conditions as the subjects from the group in Specific Aim I that acquired hearing loss.
B. These subjects would be split into groups of 4 .
C. The groups would then be treated with 62.5 mg of Ribavirin daily for 10 days beginning
at days 2,10, and 14 of the infection. The remaining 4 macaques would be the control
with no Ribavirin treatment (see Figure 17).
D. All subjects would undergo the BAER test weekly. In this experiment, they would be
exposed to the same frequency at different decibel levels in order to determine the degree
of hearing loss developed.

Expected Results: The treatment regimen of 62.5 mg was calculated based on the treatment for
humans infected with the Lassa virus.18 Currently, the drug is only effective in curbing the
disease’s symptoms if administered early, thus I would expect that the group receiving the
treatment at day two would have less severe hearing loss than those beginning the treatment at
day 14 (see Figure 18).
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One of the biggest shortcomings of this experiment is the small sample size. Both
specific aims use Cynomolgus macaques as subjects and while these organisms are ideal models
because they respond to the virus with human-like symptoms, they are highly expensive to
maintain. Thus, the results from this project might be a little skewed because of the small data
size. In order to address this, both specific
aims could be attempted using knockout or
transgenic

mice.

I

would

personally

recommend transgenic mice over knockout
mice because completely knocking out the
immune system of these mice might allow
them respond to the virus, but they might not
live long enough to be valuable to the
experiment. However, transgenic mice with
human or macaque immune cell genes would
still have functional immune systems that
could manipulated as needed. This would allow
for a larger study sample and more data results.
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CHAPTER THREE: CONCLUSION
While Lassa fever and Ebola showed up in African history within the last century, 1969
and 1979 respectively, they were both essentially forgotten until recent times.55 Within the last
couple of years there have been barely controlled epidemics of both viruses in West Africa.
According to the World Health Organization (WHO), between August 2015 and May 2016 there
were about 273 reported cases of Lassa Fever and 149 deaths in over 23 of the 36 states in
Nigeria.55 Ebola took more lives in 2014 when there was a worldwide scare relating to an
outbreak ravaging Guinea, Liberia, and Sierra Leone. A total of 28,616 cases were reported and
about 11,310 deaths.55 While the Lassa fever epidemic was restricted to African countries where
the host rat is prevalent, a total of four individuals were infected in America during the 2014
Ebola epidemic and of those four only one man died. This variation in fatalities leaves much to
be desired in the public health and epidemic sector of the affected West African countries and
begs the question: What are West African countries doing wrong?
In answering this question one must consider first of all that West Africans are
intrinsically superstitious. These epidemics originate in rural areas where most people still
believe that a lot of disease are the manifestations of the wrath of the gods. In the cities where
one might expect to find the learned and more knowledgeable members of the society, things are
only slightly better. As the tales of a disease that is ravaging the people of Liberia, Guinea, and
Senegal begin to spread, panic ensues and stories begin to spring up about ways to protect
yourself from the disease.56 During the last Ebola epidemic (2014) a lot of people tried
everything from bathing with salt water twice a day to drinking an assortment of herbal
concoctions. None of which have any scientific basis whatsoever. In March-June 2016, when the
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rumblings began of a Lassa fever epidemic in Nigeria, people stopped eating “bushmeat”.57
Bush meat, which is the West African term for wild game, includes a variety of animals from
mammals to reptiles. These animals are hunted, roasted, and sold to highest bidder.57 No one
thinks to check if the animal was sick before it was killed, or if the exposure to heat was long and
intense enough to kill all living microbes in the meat.57 Unfortunately, many of these microbes
could have variations of heat shock proteins that might be able to withstand such temperature
extremes, in which case the meat is still dangerous even after it's been roasted.57 But the people
cannot be faulted because they do not know any better. Their response is one of ignorance
because the public health infrastructure of many of these countries are subpar and lack awareness
schemes.58 One way to increase awareness is to create fact sheets that can be distributed in
schools, work places, and general social gatherings that give key details about these diseases and
how to respond to and prevent the spread of infection*.
To further put things in perspective, about 100,000 to 300,000 reported cases and 5,000
deaths from Lassa Fever might not seem significant in the large scheme of things considering
there are over 7 billion people in the world today.4 However, of those 7 billion people, 245
million of them live in West Africa, and of those West Africans 5,000 people die annually from
this disease.6 A recent study has estimated 22 million people distributed in areas of Central and
West Africa to be at risk of Ebola. It is also important to understand the fact that these death toll
numbers are not a completely accurate representation because many of the people affected by the
disease do not have access to medical care and thus cannot be counted among the reported cases.
Yet, nothing tangible is being done to address the situation. Hopefully, the research presented in
this paper will lay the framework for more investigations and begin a much-needed conversation.
*An example of a fact sheet from the World Health Organization can be found at the end of this document.59
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